The Potential Impact of the White House AI Action Plan on Healthcare

On July 23, 2025, the Trump administration released "Winning the Race: America's AI Action Plan," aimed at promoting innovation and development in artificial intelligence (AI) in the United States. The plan outlines 90 policy recommendations across multiple sectors, particularly in healthcare and life sciences, with far-reaching implications.

First, the plan's core objectives are to accelerate AI innovation, build AI infrastructure, and enhance the United States' global AI diplomacy and security influence. The plan specifically emphasizes the need for the United States to maintain a leading position in the global AI competition and proposes multiple recommendations, including promoting innovation, enhancing economic competitiveness, and safeguarding national security. These recommendations also include health-related policies such as supporting scientific research, addressing data privacy and quality issues, and promoting AI standardization.

At the same time, the Trump administration emphasizes promoting AI development through deregulation, avoiding the use of federal funds for the development of complex AI regulations. The plan proposes that the federal government will avoid excessive interference in state regulations and support innovation. The administration also directs the Office of Science and Technology Policy (OSTP) to solicit public feedback on federal regulations that impact AI innovation and recommends that the Office of Management and Budget (OMB) adjust or eliminate unnecessary regulations. However, the introduction of state-level regulations may conflict with federal policies. For example, Utah and Colorado have introduced regulations, particularly for the deployment of AI in healthcare and clinical settings, which could impact the allocation of federal funding.

Secondly, the Trump administration proposes establishing AI Centers of Excellence (regulatory sandboxes) to provide a testing environment for AI tools in healthcare. The plan also proposes that the National Institute of Standards and Technology (NIST) develop industry standards for AI, particularly in healthcare, to promote standardization. This suggests the FDA may update its regulatory framework for AI medical devices to promote transparency and the use of representative data. However, whether the previous draft guidance will be retained remains to be seen.

Furthermore, the plan notes that AI innovation relies on high-quality datasets, and the National Science and Technology Council (NSTC) will develop minimum data quality standards for fields such as biology. The plan also proposes expanding access to federal statistical data and strengthening data sharing. This could impact data privacy and security requirements in the healthcare industry, particularly regarding the coordination between federal and state regulations.

Furthermore, to promote AI-driven scientific progress, the plan encourages public-private collaboration and recommends investing in automated cloud laboratories to support scientific research. The plan also proposes incentivizing researchers to release higher-quality datasets and requiring the public use of non-sensitive datasets. These measures may accelerate data sharing, but they may also conflict with state laws regarding data privacy.

In addition, the plan places a particular emphasis on biosecurity, requiring all institutions receiving federal funding to use standardized nucleic acid synthesis tools to prevent malicious actors from exploiting biological advances. This proposal may impact research institutions related to genomics or molecular biology.

Finally, as healthcare institutions gradually adopt AI technologies, the Trump administration's AI action plan may significantly alter the relevant compliance framework. Healthcare institutions need to monitor not only federal AI policies but also coordinate with state laws and regulations. In addition to monitoring the implementation of federal plans, healthcare entities should review their AI governance systems to ensure compliance with state and federal laws.

In summary, the Trump administration's AI action plan presents numerous opportunities and challenges for the healthcare sector. As the policy progresses, healthcare institutions and life sciences research entities will face new compliance considerations and regulatory environments.